Astrana Health (ASTH) Cash & Equivalents (2010 - 2026)

Astrana Health (ASTH) has 17 years of Cash & Equivalents data on file, last reported at $478.4 million in Q1 2026.

• Quarterly Cash & Equivalents rose 85.05% year-over-year to $478.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $478.4 million (up 85.05% YoY) and the FY2025 annual result came in at $429.5 million, up 48.89% from the prior year.
• Cash & Equivalents advanced to $478.4 million in Q1 2026 per ASTH's latest filing, from $429.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $478.4 million in Q1 2026, with the low at $184.0 million in Q3 2022.
• Average Cash & Equivalents over 5 years is $314.4 million, with a median of $293.8 million recorded in 2023.
• Year-over-year, Cash & Equivalents decreased 22.78% in 2025 and surged 85.05% in 2026.
• Astrana Health's Cash & Equivalents stood at $288.0 million in 2022, then advanced by 2.01% to $293.8 million in 2023, then slipped by 1.82% to $288.5 million in 2024, then soared by 48.89% to $429.5 million in 2025, then grew by 11.39% to $478.4 million in 2026.
• Business Quant data shows ASTH's Cash & Equivalents at $478.4 million in Q1 2026, $429.5 million in Q4 2025, and $462.2 million in Q3 2025.